keyword
https://read.qxmd.com/read/38534975/expression-patterns-of-gata3-in-classical-hodgkin-lymphoma-a-clinico-pathological-study
#1
JOURNAL ARTICLE
Alexandra Papoudou-Bai, Epameinondas Koumpis, Georgia Karpathiou, Eleftheria Hatzimichael, Panagiotis Kanavaros
GATA3 is a transcription factor involved in T-cell maturation and has been previously shown to be aberrantly overexpressed in malignant Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). However, the immunophenotypes of the cell types expressing GATA3 have not been precisely characterized so far in cHL tissues. In this single-center retrospective cohort study we analyzed the expression patterns of GATA3 alone and in combination with B, T, NK or macrophage-associated markers in 73 cases with newly diagnosed cHL and investigated for a possible correlation with clinical and laboratory parameters...
February 29, 2024: Diseases (Basel)
https://read.qxmd.com/read/38521840/post-marketing-surveillance-of-the-safety-and-effectiveness-of-nivolumab-for-classic-hodgkin-lymphoma-in-japan
#2
JOURNAL ARTICLE
Akira Kawasaki, Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, Tomohiro Hoshino, Ayumi Akamatsu, Akito Kakuuchi, Kensei Tobinai
Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness of nivolumab treatment for up to 12 months in patients with relapsed/refractory cHL. Of 304 registered patients, 288 were included in safety analyses and 282 in effectiveness analyses. There were 191 (66.3%) male patients, median age was 64.0 years, and 54 patients (18...
March 23, 2024: International Journal of Hematology
https://read.qxmd.com/read/38515348/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors
#3
JOURNAL ARTICLE
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang, Hongwei Wang, Patrick Schnell, Ya Wan, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman, Nageshwar Budha
Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated improved survival benefits over standard of care for multiple cancer indications. We present the clinical rationale and data supporting tislelizumab dose recommendation in patients with advanced tumors. The phase I, first-in-human, dose-finding BGB-A317-001 study (data cutoff [DCO]: August 2017) examined the following tislelizumab dosing regimens: 0.5-10 mg/kg every 2 weeks (q2w), 2-5 mg/kg q2w or q3w, and 200 mg q3w...
March 2024: Clinical and Translational Science
https://read.qxmd.com/read/38510239/remission-of-relapsed-refractory-classical-hodgkin-lymphoma-induced-by-brentuximab-vedotin-and-pembrolizumab-combination-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#4
Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38502227/brentuximab-vedotin-and-chemotherapy-in-relapsed-refractory-hodgkin-lymphoma-a-propensity-score-matched-analysis
#5
JOURNAL ARTICLE
Julia Driessen, Fer de Wit, Alex F Herrera, Pier Luigi Zinzani, Ann S LaCasce, Peter D Cole, Craig H Moskowitz, Ramón García-Sanz, Michael Fuchs, Horst Mueller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M Zijlstra, Barbara A Hutten, Alison J Moskowitz, Marie José Kersten
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score-matched analysis encompassing individual patient data from ten clinical trials to evaluate the impact of BV in transplant-eligible R/R cHL patients. We included 768 patients, of whom 386 were treated with BV +/- chemotherapy (BV-cohort), while 382 received chemotherapy alone (chemo-cohort)...
March 19, 2024: Blood Advances
https://read.qxmd.com/read/38496566/epstein-barr-virus-orchestrates-spatial-reorganization-and-immunomodulation-within-the-classic-hodgkin-lymphoma-tumor-microenvironment
#6
Yao Yu Yeo, Huaying Qiu, Yunhao Bai, Bokai Zhu, Yuzhou Chang, Jason Yeung, Hendrik A Michel, Kyle Wright, Muhammad Shaban, Sam Sadigh, Dingani Nkosi, Vignesh Shanmugam, Philip Rock, Stephanie Pei Tung Yiu, Precious Cramer, Julia Paczkowska, Pierre Stephan, Guanrui Liao, Amy Y Huang, Hongbo Wang, Han Chen, Leonie Frauenfeld, Bidisha Mitra, Benjamin E Gewurz, Christian M Schürch, Bo Zhao, Garry P Nolan, Baochun Zhang, Alex K Shalek, Michael Angelo, Faisal Mahmood, Qin Ma, W Richard Burack, Margaret A Shipp, Scott J Rodig, Sizun Jiang
Classic Hodgkin Lymphoma (cHL) is a tumor composed of rare malignant Hodgkin and Reed-Sternberg (HRS) cells nested within a T-cell rich inflammatory immune infiltrate. cHL is associated with Epstein-Barr Virus (EBV) in 25% of cases. The specific contributions of EBV to the pathogenesis of cHL remain largely unknown, in part due to technical barriers in dissecting the tumor microenvironment (TME) in high detail. Herein, we applied multiplexed ion beam imaging (MIBI) spatial pro-teomics on 6 EBV-positive and 14 EBV-negative cHL samples...
March 7, 2024: bioRxiv
https://read.qxmd.com/read/38487720/case-report-from-sequence-to-solution-tailoring-treatment-for-transformed-follicular-lymphoma-dlbcl-through-next-generation-sequencing-study
#7
Antonin Bouroumeau, Sarah Perdikis-Prati, Noémie Lang
Immune checkpoint blockade (ICB) has indeed transformed the outlook for many advanced-stage solid tumors, yet its effectiveness in hematological malignancies has been particularly limited, with success predominantly demonstrated in classical Hodgkin lymphoma (cHL) and immune-privilege subtypes of non-Hodgkin lymphoma (NHL). In this report, we present an impactful case of a 71-year-old man grappling with refractory follicular lymphoma (rFL) that had progressed to a high-grade lymphoma, leaving no conventional treatment options on the table...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38473705/pathogenic-variants-associated-with-epigenetic-control-and-the-notch-pathway-are-frequent-in-classic-hodgkin-lymphoma
#8
JOURNAL ARTICLE
Antonio Santisteban-Espejo, Irene Bernal-Florindo, Pedro Montero-Pavon, Jose Perez-Requena, Lidia Atienza-Cuevas, Maria Del Carmen Fernandez-Valle, Ana Villalba-Fernandez, Marcial Garcia-Rojo
Classic Hodgkin lymphoma (cHL) constitutes a B-cell neoplasm derived from germinal center lymphocytes. Despite high cure rates (80-90%) obtained with the current multiagent protocols, a significant proportion of cHL patients experience recurrences, characterized by a lower sensitivity to second-line treatments. The genomic background of chemorefractory cHL is still poorly understood, limiting personalized treatment strategies based on molecular features. In this study, using a targeted next-generation sequencing (NGS) panel specifically designed for cHL research, we compared chemosensitive and chemorefractory diagnostic tissue samples of cHL patients...
February 20, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38468389/interfollicular-classic-hodgkin-lymphoma-report-of-a-case-and-a-brief-review-of-literature
#9
JOURNAL ARTICLE
Kristina Brannock, Samir B Kahwash
Interfollicular Hodgkin lymphoma (IHL) has been rarely reported in the literature and is recognized by the WHO Classification as a morphologic pattern sometimes seen in mixed cellularity classic Hodgkin lymphoma (CHL). The changes may be subtle due to preservation of architecture. We report a case of a 9-year-old male with IHL showing preserved follicular architecture but with the presence of interfollicular infiltrates consisting of eosinophils, plasma cells, and Hodgkin-Reed-Sternberg (HRS) cells. Immunophenotyping confirmed the morphologic suspicion for IHL...
March 11, 2024: Pediatric and Developmental Pathology
https://read.qxmd.com/read/38454623/texture-analysis-of-18f-fdg-pet-ct-and-cect-prediction-of-refractoriness-of-hodgkin-lymphoma-with-mediastinal-bulk-involvement
#10
JOURNAL ARTICLE
Elisabetta M Abenavoli, Flavia Linguanti, Matilde Anichini, Vittorio Miele, Francesco Mungai, Marianna Palazzo, Luca Nassi, Benedetta Puccini, Ilaria Romano, Benedetta Sordi, Roberto Sciagrà, Gabriele Simontacchi, Alessandro M Vannucchi, Valentina Berti
To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F-FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast-Enhanced Computed Tomography scan (CECT), together with clinical data, in predicting first-line therapy refractoriness (R) of classical HL (cHL) with mediastinal bulk involvement...
March 2024: Hematological Oncology
https://read.qxmd.com/read/38454451/camrelizumab-plus-gemcitabine-and-oxaliplatin-for-relapsed-or-refractory-classical-hodgkin-lymphoma-a-phase-ii-trial
#11
JOURNAL ARTICLE
Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
BACKGROUND: Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R/R cHL patients. METHODS: Transplant-eligible patients with R/R cHL were enrolled and received two 14-day cycles of camrelizumab 200 mg intravenously (IV) and two 28-day cycles of camrelizumab 200 mg IV, gemcitabine 1000 mg/m2 IV, and oxaliplatin 100 mg/m2 IV on days 1 and 15...
March 7, 2024: BMC Medicine
https://read.qxmd.com/read/38447253/epstein-barr-virus-latency-patterns-in-polymorphic-lymphoproliferative-disorders-and-lymphomas-in-immunodeficiency-settings-diagnostic-implications
#12
JOURNAL ARTICLE
Ashley K Volaric, Atif Saleem, Sheren F Younes, Shuchun Zhao, Yasodha Natkunam
Epstein-Barr virus (EBV) is responsible for many B cell lymphoproliferative disorders (LPD) spanning subclinical infection to immunodeficiency-related neoplasms. EBV establishes a latent infection in the host B cell as defined histologically by the expression of EBV latent membrane proteins and nuclear antigens. Herein, we characterize the latency patterns of immunodeficiency-related neoplasms including post-transplant lymphoproliferative disorders (PTLD) and therapy-related LPD (formerly iatrogenic) with latent membrane protein-1 (LMP-1) and EBV nuclear antigen-2 (EBNA-2) immunohistochemistry...
February 29, 2024: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38430902/classic-central-nervous-system-hodgkin-lymphoma-masquerading-as-left-sphenoid-wing-meningioma-a-case-report
#13
Khalida Walizada, Mohammad Mohsin Arshad, Mohsin Khan, Ghanem Salman Al Sulaiti
INTRODUCTION AND IMPORTANCE: Classic Hodgkin Lymphoma with an incidence of 2-3 cases per 100,000 population affects the Central Nervous System in 0.02 % of cases (Gerstner et al., 2008; Brice et al., 2021; Morawa et al., 2007). CNS lymphoma, contributing to 0.22 % of Central Nervous System tumors, is the uncommon extra-nodal manifestation of Hodgkin's Disease (Brice et al., 2021; Henkenberens et al., 2014). It affects the nervous system secondary to systemic lymphoma or the relapse of the disease (Gerstner et al...
February 28, 2024: International Journal of Surgery Case Reports
https://read.qxmd.com/read/38406538/circulating-tumor-dna-for-monitoring-classic-hodgkin-lymphoma-patients-correlation-with-fdg-pet-ct
#14
JOURNAL ARTICLE
Sara Fernández, Laura Cereceda, Eva Díaz, Sasha Figueroa, Laura Reguera, Victoria Menéndez, José L Solórzano, Carlos Montalbán, Mónica Estévez, Juan F García
The value of circulating tumor DNA (ctDNA) as a biomarker of disease activity in classic Hodgkin lymphoma (cHL) patients has not yet been well established. By profiling primary tumors and ctDNA, we identified common variants between primary tumors and longitudinal plasma samples in most of the cases, confirming high spatial and temporal heterogeneity. Although ctDNA analyses mirrored HRS cell genetics overall, the prevalence of variants shows that none of them can be used as a single biomarker. Conversely, the estimation of hGE/mL, based on measures of total ctDNA, reflects disease activity and is almost perfectly correlated with standard parameters such as PET/CT that are associated with refractoriness...
February 2024: EJHaem
https://read.qxmd.com/read/38403773/rare-co-occurrence-of-spinal-cord-hemorrhage-from-radiation-induced-cavernous-hemangioma-and-classical-hodgkin-lymphoma-post-transplant-lymphoproliferative-disorder
#15
JOURNAL ARTICLE
Takahiro Shimizu, Yu Nagashima, Takashi Matsukawa, Akihiko Mitsutake, Mizuho Kawai, Yurino Horiuchi, Keishi Yokoyama, Kensuke Takaoka, Yuya Kurihara, Kazuhiro Toyama, Kaori Sakuishi, Mineo Kurokawa, Tatsushi Toda
Post-transplant lymphoproliferative disorders (PTLDs) are lymphoproliferative diseases that occur after solid organ transplantation or hematopoietic stem cell transplantation (HSCT). The development of PTLD is often associated with reactivation of Epstein-Barr virus (EBV). A 26-year-old woman with a history of HSCT and total-body irradiation developed spinal cord hemorrhage from a radiation-induced cavernous hemangioma (RICH) shortly after the development of classical Hodgkin lymphoma PTLD with EBV reactivation...
February 26, 2024: Internal Medicine
https://read.qxmd.com/read/38398216/baseline-igm-amounts-can-identify-patients-with-poor-outcomes-results-from-a-real-life-single-center-study-on-classical-hodgkin-lymphoma
#16
JOURNAL ARTICLE
Andrea Duminuco, Gabriella Santuccio, Annalisa Chiarenza, Amalia Figuera, Giovanna Motta, Anastasia Laura Caruso, Alessandro Petronaci, Massimo Ippolito, Claudio Cerchione, Francesco Di Raimondo, Alessandra Romano
Hodgkin Lymphoma (HL) is characterized by an inflammatory background in which the reactive myeloid cells may exert an immune-suppressive effect related to the progression of the disease. Immunoglobulin M is the first antibody isotype produced during an immune response, which also plays an immunoregulatory role. Therefore, we investigated if, as a surrogate of defective B cell function, it could have any clinical impact on prognosis. In this retrospective, observational, single-center study, we evaluated 212 newly diagnosed HL patients, including 132 advanced-stage...
February 18, 2024: Cancers
https://read.qxmd.com/read/38367994/chronic-diarrhoea-and-ichthyosis-vulgaris-a-rare-presentation-of-hodgkin-s-lymphoma
#17
JOURNAL ARTICLE
Jessica Michelle Allen, Haley M Simpson, Gray Jodon
A man in his 30s presented with several months of non-bloody diarrhoea and nausea along with conjunctivitis, diffuse ichthyosis and cellulitis in the setting of progressive neck swelling. He was ultimately diagnosed with nodular sclerosing Hodgkin's lymphoma after undergoing a broad infectious, rheumatological and neoplastic workup. This represents a rare presentation of classic Hodgkin's lymphoma and demonstrates the known alteration of cellular immunity in Hodgkin's lymphoma alongside manifestations of the profound inflammatory state associated with the disease...
February 17, 2024: BMJ Case Reports
https://read.qxmd.com/read/38358226/interfollicular-hodgkin-s-lymphoma-a-diagnostic-challenge-for-pathologists
#18
Maneesh K Vijay, Neha Sethi
Interfollicular Hodgkin's lymphoma (IFHL) is a rare pattern of classical Hodgkin's lymphoma (CHL) showing reactive follicular hyperplasia with involvement of the interfollicular area by HL. Two cases are reported in this study having primary IFHL out of total of 500 cases of CHL reported at our center. Diagnosis of IFHL was made on the basis of morphological and immunohistochemical features. As they represent an early stage of the disease, their identification and awareness s very important to get proper treatment at its earliest...
2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38358207/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-with-reed-sternberg-like-cells-with-no-convincing-evidence-of-classic-hodgkin-lymphoma
#19
JOURNAL ARTICLE
Latha K Abraham, Mobin Paul
No abstract text is available yet for this article.
2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38356485/epstein-barr-virus-promotes-tumorigenicity-and-worsens-hodgkin-lymphoma-prognosis-by-activating-jak-stat-and-nf-%C3%AE%C2%BAb-signaling-pathways
#20
JOURNAL ARTICLE
Mohamed Ali Alabiad, Warda M M Said, Rema H Faraj Saad, Rawda Balata, Asmaa A Mahmoud, Elsayed Anany Metwally, Amany Mohamed Shalaby, Walaa Samy, Ahmed M Yehia, Amar Ibrahim Omar Yahia, Mohammed Alorini, Doaa I Abdelrahman
BACKGROUND: Epstein-Barr virus (EBV) is detected in 40% of patients with Hodgkin lymphoma (HL). During latency, EBV induces epigenetic alterations to the host genome and decreases the expression of pro-apoptotic proteins. The present study aimed to evaluate the expression levels of mRNA molecules and the end product of proteins for the JAK/STAT and NF-κB pathways, and their association with clinicopathological and prognostic parameters in patients with EBV-positive and -negative classical Hodgkin lymphoma (CHL)...
February 2024: Iranian Journal of Medical Sciences
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.